We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)
Read MoreHide Full Article
Sanofi (SNY - Free Report) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
Overview
Sanofi is the fourth largest pharmaceutical company in the world by revenue, bringing in $40.9 billion last year. It is also the seventh largest by market share, with 4.11%. Sanofi specializes in seven therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Its subsidiary, Sanofi Pasteur, is the largest dedicated vaccine producer in the world.
Sanofi’s most popular medicines include Latnus, Placix and, Lovenox. Latnus is currently Sanofi’s most successful drug, bringing about $4.9 billion in revenue last year. It is a drug that controls blood sugar in diabetics with a once daily injection. Lovenox and Placix are anti-clotting and blood-thinning drugs respectively.
Unknown to most, Sanofi also manufactures many popular over the counter brands. Products such as Gold Bond, Rolaids, Selsun Blue, and Allegra can all be found in drug stores across the country and are steady revenue streams for Sanofi.
On Wednesday, Sanofi acquired the OTC rights to popular flu medicine, Tamiflu, from competitor Roche. Sanofi is now attempting to get Tamiflu approved by the FDA for OTC sales, hoping to cash in on convenience. Roche, meanwhile, has another flu drug in the works called Xofluza, which the company says is faster acting and stronger than Tamiflu. Therefore, it looks like it will be a battle between the two companies to see if consumers will go through the extra hassle of getting a prescription for a stronger medicine, or just chose the quicker and easier access treatment.
Outlook
Our Zacks Consensus Estimate predicts Q2 revenue of $9.88 billion, a 1.24% bump over last year’s Q2 sales. For each of the past four quarters, revenues have declined year-over-year by an average of 1.4%. Hopefully, Sanofi can meet projections and have a positive quarter, which may boost SNY stock.
Although revenues have gone down the past few quarters, earnings have managed to stay in the black. Earnings have not been increasing greatly, however, with an average year-over-year jump of just 0.94% over the past 8 quarters. Earnings this quarter are projected to fall by 6.79% to $0.69. This estimate is, however, up from our $0.66 estimate 90 days ago.
Estimates for next quarter’s EPS call for 5.61% growth to $1.13 a share. This would mark an all-time high for the company. For all of 2019, estimates show just a 0.62% earnings increase from last year. Estimates also show 8.15% EPS growth for 2020, which would be the company’s largest single year EPS growth since 2008.
Since the beginning of 2019, Sanofi’s forward P/E of 12.4x has dropped relative to its peer-group, suggesting that it may currently be undervalued. Its peer-group—that includes Merck (MRK - Free Report) , GlaxoSmithKline (GSK - Free Report) , AbbVie (ABBV - Free Report) , Pfizer (PFE - Free Report) , and others—has an average forward P/E of 14.29.
Recent News
The FDA accepted an application for approval of Sanofi’s relapsed/refractory multiple myeloma drug, isatuximab. This drug has undergone successful phase III trials and is still in other clinical trials to possibly treat other types of hematologic malignancies and solid tumors.
Sanofi has a strong pipeline in addition to isatuximab. It includes several new biologics and vaccines in late-stage development. A promising pipeline is always important for drug companies, as investors need to see how strong the future of the company looks after current patents inevitably run out.
Bottom Line
Sanofi currently holds a Zacks Rank #2 (Buy), due to upward earnings estimate revisions for this fiscal year and next. Sanofi likely won’t report stellar earnings when it releases its quarterly results before the market opens on Monday, July 29. But with a strong pipeline in development and possible OTC Tamiflu boosting future revenues, Sanofi has strong potential to raise earnings over the coming quarters and into 2020.
We are reissuing this article to correct a mistake. A previous version of this article refered to "Xofluza" as "Zofluza." The original article, issued July 24, 2019, should no longer be relied upon.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Image: Bigstock
What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)
Sanofi (SNY - Free Report) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
Overview
Sanofi is the fourth largest pharmaceutical company in the world by revenue, bringing in $40.9 billion last year. It is also the seventh largest by market share, with 4.11%. Sanofi specializes in seven therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Its subsidiary, Sanofi Pasteur, is the largest dedicated vaccine producer in the world.
Sanofi’s most popular medicines include Latnus, Placix and, Lovenox. Latnus is currently Sanofi’s most successful drug, bringing about $4.9 billion in revenue last year. It is a drug that controls blood sugar in diabetics with a once daily injection. Lovenox and Placix are anti-clotting and blood-thinning drugs respectively.
Unknown to most, Sanofi also manufactures many popular over the counter brands. Products such as Gold Bond, Rolaids, Selsun Blue, and Allegra can all be found in drug stores across the country and are steady revenue streams for Sanofi.
On Wednesday, Sanofi acquired the OTC rights to popular flu medicine, Tamiflu, from competitor Roche. Sanofi is now attempting to get Tamiflu approved by the FDA for OTC sales, hoping to cash in on convenience. Roche, meanwhile, has another flu drug in the works called Xofluza, which the company says is faster acting and stronger than Tamiflu. Therefore, it looks like it will be a battle between the two companies to see if consumers will go through the extra hassle of getting a prescription for a stronger medicine, or just chose the quicker and easier access treatment.
Outlook
Our Zacks Consensus Estimate predicts Q2 revenue of $9.88 billion, a 1.24% bump over last year’s Q2 sales. For each of the past four quarters, revenues have declined year-over-year by an average of 1.4%. Hopefully, Sanofi can meet projections and have a positive quarter, which may boost SNY stock.
Although revenues have gone down the past few quarters, earnings have managed to stay in the black. Earnings have not been increasing greatly, however, with an average year-over-year jump of just 0.94% over the past 8 quarters. Earnings this quarter are projected to fall by 6.79% to $0.69. This estimate is, however, up from our $0.66 estimate 90 days ago.
Estimates for next quarter’s EPS call for 5.61% growth to $1.13 a share. This would mark an all-time high for the company. For all of 2019, estimates show just a 0.62% earnings increase from last year. Estimates also show 8.15% EPS growth for 2020, which would be the company’s largest single year EPS growth since 2008.
Since the beginning of 2019, Sanofi’s forward P/E of 12.4x has dropped relative to its peer-group, suggesting that it may currently be undervalued. Its peer-group—that includes Merck (MRK - Free Report) , GlaxoSmithKline (GSK - Free Report) , AbbVie (ABBV - Free Report) , Pfizer (PFE - Free Report) , and others—has an average forward P/E of 14.29.
Recent News
The FDA accepted an application for approval of Sanofi’s relapsed/refractory multiple myeloma drug, isatuximab. This drug has undergone successful phase III trials and is still in other clinical trials to possibly treat other types of hematologic malignancies and solid tumors.
Sanofi has a strong pipeline in addition to isatuximab. It includes several new biologics and vaccines in late-stage development. A promising pipeline is always important for drug companies, as investors need to see how strong the future of the company looks after current patents inevitably run out.
Bottom Line
Sanofi currently holds a Zacks Rank #2 (Buy), due to upward earnings estimate revisions for this fiscal year and next. Sanofi likely won’t report stellar earnings when it releases its quarterly results before the market opens on Monday, July 29. But with a strong pipeline in development and possible OTC Tamiflu boosting future revenues, Sanofi has strong potential to raise earnings over the coming quarters and into 2020.
We are reissuing this article to correct a mistake. A previous version of this article refered to "Xofluza" as "Zofluza." The original article, issued July 24, 2019, should no longer be relied upon.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>